These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38744472)

  • 1. CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis.
    Song X; Jiang C; Yu M; Lu C; He X
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1597-1605. PubMed ID: 38744472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
    Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
    PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells.
    Madan U; Verma B; Awasthi A
    Eur J Immunol; 2024 Jul; 54(7):e2350847. PubMed ID: 38643381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Application for Cenicriviroc, a Dual CCR2/CCR5 Antagonist, in the Treatment of Painful Diabetic Neuropathy in a Mouse Model.
    Bober A; Piotrowska A; Pawlik K; Ciapała K; Maciuszek M; Makuch W; Mika J
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
    Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
    J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic alcohol-induced neuroinflammation involves CCR2/5-dependent peripheral macrophage infiltration and microglia alterations.
    Lowe PP; Morel C; Ambade A; Iracheta-Vellve A; Kwiatkowski E; Satishchandran A; Furi I; Cho Y; Gyongyosi B; Catalano D; Lefebvre E; Fischer L; Seyedkazemi S; Schafer DP; Szabo G
    J Neuroinflammation; 2020 Oct; 17(1):296. PubMed ID: 33036616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of intrahepatic monocyte recruitment by Cenicriviroc and extracellular matrix degradation by MMP1 synergistically attenuate liver inflammation and fibrogenesis in vivo.
    Geervliet E; Karkdijk E; Bansal R
    Sci Rep; 2024 Jul; 14(1):16897. PubMed ID: 39043893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice.
    Ambade A; Lowe P; Kodys K; Catalano D; Gyongyosi B; Cho Y; Iracheta-Vellve A; Adejumo A; Saha B; Calenda C; Mehta J; Lefebvre E; Vig P; Szabo G
    Hepatology; 2019 Mar; 69(3):1105-1121. PubMed ID: 30179264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis.
    Tokuyama H; Ueha S; Kurachi M; Matsushima K; Moriyasu F; Blumberg RS; Kakimi K
    Int Immunol; 2005 Aug; 17(8):1023-34. PubMed ID: 16000328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice.
    Chen G; Yu Y; Zhu Y; Nagashimada M; Wang Y; Nagata N; Xu L
    Endocrinology; 2024 May; 165(7):. PubMed ID: 38862137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy.
    Kwiatkowski K; Pawlik K; Ciapała K; Piotrowska A; Makuch W; Mika J
    Front Immunol; 2020; 11():615327. PubMed ID: 33408720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
    Files DC; Tacke F; O'Sullivan A; Dorr P; Ferguson WG; Powderly WG
    PLoS Pathog; 2022 Jun; 18(6):e1010547. PubMed ID: 35749425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosa repair mechanisms of Tong-Xie-Yao-Fang mediated by CRH-R2 in murine, dextran sulfate sodium-induced colitis.
    Gong SS; Fan YH; Wang SY; Han QQ; Lv B; Xu Y; Chen X; He YE
    World J Gastroenterol; 2018 Apr; 24(16):1766-1778. PubMed ID: 29713130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the beneficial effects of RS504393, maraviroc and cenicriviroc on neuropathic pain-related symptoms in rodents: behavioral and biochemical analyses.
    Kwiatkowski K; Ciapała K; Rojewska E; Makuch W; Mika J
    Int Immunopharmacol; 2020 Jul; 84():106540. PubMed ID: 32402949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DIREN mitigates DSS-induced colitis in mice and attenuates collagen deposition via inhibiting the Wnt/β-catenin and focal adhesion pathways.
    Lai W; Wang Y; Huang C; Xu H; Zheng X; Li K; Wang J; Lou Z
    Biomed Pharmacother; 2024 Jun; 175():116671. PubMed ID: 38678963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine.
    Andres PG; Beck PL; Mizoguchi E; Mizoguchi A; Bhan AK; Dawson T; Kuziel WA; Maeda N; MacDermott RP; Podolsky DK; Reinecker HC
    J Immunol; 2000 Jun; 164(12):6303-12. PubMed ID: 10843684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmdmdx-4Cv) mice.
    Liang F; Giordano C; Shang D; Li Q; Petrof BJ
    PLoS One; 2018; 13(3):e0194421. PubMed ID: 29561896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis.
    Raghu H; Lepus CM; Wang Q; Wong HH; Lingampalli N; Oliviero F; Punzi L; Giori NJ; Goodman SB; Chu CR; Sokolove JB; Robinson WH
    Ann Rheum Dis; 2017 May; 76(5):914-922. PubMed ID: 27965260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy.
    Bowler S; Siriwardhana C; Mitchell BI; D'Antoni ML; Ogata-Arakaki D; Souza S; Yee R; Gangcuangco LMA; Chow DC; Ndhlovu LC; Shikuma C
    HIV Res Clin Pract; 2019; 20(4-5):123-129. PubMed ID: 32013805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.